Juvisync combines Januvia (sitagliptin), the glucose-lowering medication with the cholesterol-lowering medication Zocor (simvastatin).
According to the company, Juvisync is said to provide blood sugar-lowering benefits of a DPP-4 inhibitor and the cholesterol-lowering benefits of simvastatin, with a dose of single tablet in a day.
The approval by FDA is followed by clinical bioequivalence studies in healthy subjects who showed administration of Juvisync is equivalent to co-administration of corresponding doses of the two individual medications, sitagliptin and simvastatin, as separate tablets.